Stock RNAC CARTESIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
34.72 USD +10.43% Intraday chart for Cartesian Therapeutics, Inc. +41.31% +67.88%
May. 24 Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
May. 22 Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate MT

Evolution of the average Target Price on Cartesian Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4d94d6cd842e.6wRwcMeIiTRQK8aUhpqQlqG-6XD44QSwgSIrPDSQmBY.qFYRO6rG81o5HqPysq7_2sDor0GVhWuBzVBlf0XY-kDTXhNC9NDgTWdtrQ~1ddb1407c94e36734cea4df637eb31c6

Analyst Recommendations on Cartesian Therapeutics, Inc.

Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
SELECTA BIOSCIENCES : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
SELECTA BIOSCIENCES : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
SELECTA BIOSCIENCES : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.72 USD
Average target price
42.6 USD
Spread / Average Target
+22.70%
High Price Target
54 USD
Spread / Highest target
+55.53%
Low Price Target
38 USD
Spread / Lowest Target
+9.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cartesian Therapeutics, Inc.

Mizuho Securities
Leerink Partners
Needham & Co.
HC Wainwright
Canaccord Genuity
SVB Securities LLC
BTIG
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.